首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1264361篇
  免费   78371篇
  国内免费   1879篇
耳鼻咽喉   17909篇
儿科学   41736篇
妇产科学   34275篇
基础医学   179460篇
口腔科学   35093篇
临床医学   109753篇
内科学   237862篇
皮肤病学   28881篇
神经病学   94201篇
特种医学   53344篇
外国民族医学   303篇
外科学   191539篇
综合类   22850篇
现状与发展   1篇
一般理论   271篇
预防医学   90217篇
眼科学   28510篇
药学   99042篇
  9篇
中国医学   2942篇
肿瘤学   76413篇
  2018年   15076篇
  2017年   12925篇
  2016年   13630篇
  2015年   16351篇
  2014年   19946篇
  2013年   26346篇
  2012年   40894篇
  2011年   38136篇
  2010年   21765篇
  2009年   22139篇
  2008年   33284篇
  2007年   36249篇
  2006年   36944篇
  2005年   42913篇
  2004年   42824篇
  2003年   37474篇
  2002年   31824篇
  2001年   64038篇
  2000年   63542篇
  1999年   55917篇
  1998年   13281篇
  1997年   11577篇
  1996年   11598篇
  1995年   10809篇
  1994年   9813篇
  1993年   9263篇
  1992年   43349篇
  1991年   42083篇
  1990年   41762篇
  1989年   40087篇
  1988年   36226篇
  1987年   35131篇
  1986年   33167篇
  1985年   30861篇
  1984年   22242篇
  1983年   18584篇
  1982年   9721篇
  1979年   20257篇
  1978年   13418篇
  1977年   11781篇
  1976年   10230篇
  1975年   12185篇
  1974年   14381篇
  1973年   13650篇
  1972年   13165篇
  1971年   12517篇
  1970年   11558篇
  1969年   11136篇
  1968年   9925篇
  1967年   9021篇
排序方式: 共有10000条查询结果,搜索用时 265 毫秒
1.
2.
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional...  相似文献   
3.
Molnár  B.  Aroca  S.  Dobos  A.  Orbán  K.  Szabó  J.  Windisch  P.  Stähli  A.  Sculean  A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with...  相似文献   
4.
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation.  相似文献   
5.
6.
7.
8.
9.
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号